Shareholder Meeting – Part 3
Parkinson’s
-The move to Europe was because of many factors. Cost, availability, LUND, etc..
-LUND will not be conducting the trial. They are PHDs not MDs. MDs will be needed.
-MJF gave us 300K for the preclinical
-Targeting more cognitive improvements as opposed to physical.
-It will not be an expensive trial
Funding
-28 million – plenty to do all trials
-They will look for other funding opportunities
-He expects more funding from the Australian government
IP
-They have many patents already and many have been filed or are being filed.
-Compositional Matter
-Crystallization of compound
-Method of use for all indications
-Processing and Manufacturing
Miscellaneous
-Biogen MTA – Long shot, too early. Next step is to do a model study. Missling said they have enough on their plate already.
-Organizations that have done testing – Angelman, Fragile X, etc. were excited and said it was the strongest signal they have ever seen. Missling offers these companies/organizations the opportunity to do testing on their dime. Some accept and some don’t.
-He did not rule out anything – partnerships, buyouts, etc. He said he will take things and evaluate them if and when they come.
-**He said he will be “loading up” again shortly. “Why wouldn’t you at these prices”. He couldn’t buy more because of the shareholder’s meeting but will.
-He said they already have some protection from a takeover and really did not feel the need to go for the blank check preferreds again. Maybe next year.
-They have a good relationship with the FDA
-He said that when people look back and see what we did and why, they will understand
-Distribution and manufacturing – early stages of planning and discussion.
Final Thoughts Coming. Maybe not tonight though.
Market Data 
Markets 
AI
